Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR





GREATER DES MOINES, Iowa, Jan. 31, 2024 /PRNewswire/ — The Greater Des Moines Partnership unveiled its 2024 Strategic Priorities and shared its 2023 accomplishments at its Annual Dinner on Thursday, Jan. 25 at the Community Choice Credit Union Convention Center at the Iowa Events Center.

The Partnership’s 2023 results demonstrated growth and increased momentum in Greater Des Moines (DSM). The Partnership announced its economic development work with state and local partners that resulted in 31 relocation and expansion projects and $2 billion in capital investment in DSM.

The Partnership also unveiled its 2023 Annual Report to highlight the prior year’s successes at the Annual Dinner. View the full report.

“Our community has long been successful because of countless people who have stepped up when their time comes to lead. We work together to prepare for the future, to create a shared vision, and to work as one to push the needle on growth and making our region even stronger,” said Mike McCoy, CEO of NCMIC Group and 2023 Board Chair of The Partnership. “In 2023, the Greater Des Moines region saw great strides in economic advancements, innovative talent engagement and support for placemaking projects including the Des Moines International Airport terminal project.”

During the program, Partnership 2024 Board Chair David Stark, Chief of Government Affairs & Philanthropy at UnityPoint Health, unveiled the six Strategic Priorities for The Partnership in 2024.

The Partnership’s 2024 Strategic Priorities are:

  • Economic Development: Increase economic development project leads, expand pipeline of prospects, assist business location and expansions, promote DSM RFI Ready program and intentionally leverage data to drive economic development efforts.
  • Talent Development: Expand internship and leadership development programming to grow local talent and activate the DSM Workforce Collaborative recommendations. The Partnership will work with Principal Financial Group® and the Principal® Charity Classic to create a new community-driven work-based learning program to prepare high school students for the future of work. The Partnership will also be launching a new program that connects highly engaged prospective talent with DSM super connectors and ambassadors.
  • Quality of Life Placemaking Projects: Enhance the vibrancy of DSM through supporting regional quality of life placemaking projects throughout the region. Assist with project needs that will lead to development, funding sources, messaging, storytelling, advocacy and regional engagement for projects.
  • Global DSM Talent Study: Conduct Global DSM Talent study. From 2010 – 2020, the DSM region increased its foreign-born population by nearly 50% — the second-highest rate in the nation. This priority will build on that momentum with intentional steps that can be taken to help attract and retain talent from around the world. 
  • Activating the Capital Crossroads Roadmap: Support implementation of Capital Crossroads roadmap with regional partners. Community visioning is one of the elements of the community’s success. Regional partners have unveiled the Capital Crossroads: Central Iowa’s Roadmap to Opportunity and Prosperity for All.  
  • Regional Storytelling: Amplify the DSM USA story loud, bold and broad through media relations and website efforts for strategic storytelling and implement a new regional community integration strategy to advance rural, suburban and urban relationships.

“These are priorities that our Investors, Affiliate Chambers and Members asked for, and we are prepared to tackle them as One Partnership,” Stark said. “Maintaining a healthy community requires continuous work. We must continue to identify opportunities and ask “what’s next” to stay on the cutting edge as a premier place for economic development and talent attraction.”

Learn more on The Partnership’s website.

The Partnership also announced its Board of Directors and Executive Board. In addition to Stark’s role as Chair and McCoy’s role as Past Chair, Jeff Rommel with Nationwide and Miriam Erickson Brown with Anderson Erickson Dairy will serve as Vice Chairs, Rowena Crosbie with Tero International, Inc. will serve as Secretary and Rick Tiwald with Deloitte will serve as Treasurer. See the full list of the 2024 Greater Des Moines Partnership Board of Directors and Executive Board.

This year’s Annual Dinner keynote presentation was headlined by former NFL quarterback Alex Smith. Smith played for 16 seasons in the NFL for San Francisco, Kansas City and Washington, and was selected to three Pro Bowls as one of the most outstanding players in the league. He overcame a life-threatening injury to make it back on the field against the odds. Smith was able to share a message of teamwork and overcoming adversity.

About the Greater Des Moines Partnership
The Greater Des Moines Partnership is the economic and community development organization that serves Greater Des Moines (DSM), Iowa. Together with 23 Affiliate Chambers of Commerce, more than 6,500 Regional Business Members and more than 400 Investors, The Partnership drives economic growth with one voice, one mission and as one region. Through innovation, strategic planning and global collaboration, The Partnership grows opportunity, helps create jobs and promotes DSM as the best place to build a business, a career and a future. Learn more at

Kyle Oppenhuizen
[email protected]
(515) 286-4972
Learn More About DSM USA

Logo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading